Where BPC-157 stands with the FDA in 2026

Approved drug vs compounded drug

An FDA-approved drug has been through clinical trials and an FDA review of its safety, effectiveness and manufacturing. BPC-157 has never gone through that process for any condition, and no company has an approved BPC-157 product.

A compounded drug is prepared by a licensed pharmacy for an individual patient with a prescription. The FDA is clear that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness or quality before they are dispensed. Even if BPC-157 is eventually added to the compounding list, it would remain an unapproved drug.

How the compounding rules work

Under section 503A of the federal Food, Drug, and Cosmetic Act, a pharmacy generally may compound with a bulk ingredient only if it has a USP monograph, is a component of an FDA-approved drug, or appears on the FDA's 503A bulks list. BPC-157 fits none of these today.

While the bulks list is being built, the FDA sorts nominated substances into interim categories. Category 1 substances may be compounded under the agency's interim policy; Category 2 substances raise significant safety concerns; Category 3 lacked enough information to evaluate. Substances nominated on or after January 7, 2025 are not being placed in these categories.

A timeline of recent changes

• 2023: The FDA listed BPC-157 among bulk substances that may present significant safety risks, citing possible immune reactions for certain routes and a lack of human safety information.
• April 2026: The FDA's safety-risk page moved BPC-157 to a section of substances 'nominated but withdrawn' by the nominators. This was not a finding that BPC-157 is safe and did not place it in Category 1.
• July 23, 2026: The Pharmacy Compounding Advisory Committee reviewed BPC-157 for ulcerative colitis. FDA staff recommended against listing, citing a lack of evidence of effectiveness and difficulty setting quality standards. The committee voted to recommend listing; RAPS reported an 8 to 6 vote with one abstention.
• October 2026: No final FDA decision or rule adding BPC-157 to the bulks list has been published.

What the advisory vote does and does not mean

The FDA states that advisory committees make non-binding recommendations. After a vote, the agency reviews the recommendation, public comments and the record, then decides whether to propose a rule. A proposed rule would go through notice and comment before any final listing. In other words, the vote did not by itself change federal compounding rules.

The vote also does not show that BPC-157 works. FDA staff told the committee there was a lack of evidence to support effectiveness for ulcerative colitis, and the agency had received a small number of adverse event reports it could not clearly attribute to the peptide.

Why 'research chemical' products are a different risk

BPC-157 is widely sold online in vials labeled for research use only. These are not prescriptions and are not made under pharmacy standards, so identity, purity, dose and sterility are unknown. The FDA warns that consumers buying compounded or unapproved drugs online may not know who made them or whether quality standards were met.

The U.S. Anti-Doping Agency notes there are no human clinical trials establishing efficacy and that it is unknown whether a safe dose exists. Some human studies appear to have been stopped without published results.

State law and sport

Federal rules are only part of the picture. State pharmacy boards set their own requirements, which can be stricter than federal rules. Even after any federal listing, state rules on prescribing and dispensing would still apply.

For athletes, the answer is simpler. BPC-157 is prohibited at all times under the World Anti-Doping Agency's S0 non-approved substances category, so anyone subject to drug testing should not use it.

Questions to ask any peptide provider

• Is a licensed clinician reviewing my history before prescribing?
• Which licensed pharmacy dispenses it, and in which state is it licensed?
• On what legal basis is the pharmacy compounding this substance right now?
• Will I receive a label with the ingredient, strength and lot number?
• What happens to my prescription if federal or state rules change?

How HealifyMD handles this

A licensed clinician reviews your history, including cancer history and medications, and decides whether BPC-157 is reasonable for you at all. A prescription is sent only to a licensed U.S. pharmacy that confirms it can lawfully dispense the product under current federal and state rules. If those rules change, your plan changes with them, and we will tell you.

BPC-157 is a compounded medication, is not FDA-approved and has not been reviewed by the FDA for safety, effectiveness or quality. The price starts at $250/month, or $450 for two months ($225/month), with no membership fee, confirmed at the eligibility review; labs are priced separately.